by Fred Dumais | Sep 9, 2024 | News Release
MONTREAL, QUEBEC , September 9, 2024 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the third quarter ended July 31, 2024...
by Fred Dumais | Sep 3, 2024 | Communiqué de presse
MONTRÉAL (QUÉBEC), le 3 septembre 2024 – Valeo Pharma inc. (TSX : VPH, FSE : VP2) (la « Société » ou « Valeo Pharma »), une société pharmaceutique canadienne, a annoncé aujourd’hui qu’elle a conclu une entente (l”«Amendement » ) avec Sagard...
by Fred Dumais | Sep 3, 2024 | News Release
MONTREAL, QUEBEC, September 3, 2024 – Valeo Pharma Inc. (TSX: VPH, FSE: VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, today announced that it has entered into an agreement (the “Amendment”) with Sagard Healthcare Royalty Partners, LP...
by Fred Dumais | Aug 29, 2024 | Communiqué de presse
MONTRÉAL (QUÉBEC), le 29 août 2024 – Valeo Pharma inc. (TSX : VPH, OTCQB : VPHIF, FSE : VP2) (la « Société » ou « Valeo Pharma »), une société pharmaceutique canadienne, a annoncé aujourd’hui que la Société retire volontairement ses actions...
by Fred Dumais | Aug 29, 2024 | News Release
MONTREAL, QUEBEC, August 29, 2024 – Valeo Pharma Inc. (TSX: VPH, OTCQB: VPHIF, FSE: VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, today announced that the Company is voluntarily delisting its Class A shares from trading on the OTCQB Venture...
